Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

MBK Partners Sells Luye Pharma Stake to Fellow PE Funds

publication date: Mar 2, 2012
In an unusual move, one private equity fund has sold its majority ownership in a China pharma to three other funds, a rare fund-to-fund transaction. MBK Partners, a PE group based in Korea, sold its 77% interest in Luye Pharma Group, a Singapore listed company that operates mainly in China. According to the Wall Street Journal, the transaction shows that investor funds have more investable capital than attractive targets, while public valuations are low by comparison. The selling price has not been disclosed. More details.....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital